![]() You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself.This card shows analyst upgrades/downgrades for Blueprint Medicines Corp. Simply Wall St has no position in any stocks mentioned. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. We aim to bring you long-term focused analysis driven by fundamental data. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. This article by Simply Wall St is general in nature. ![]() Alternatively, email editorial-team (at). Have feedback on this article? Concerned about the content? Get in touch with us directly. At Simply Wall St, we have a full range of analyst estimates for Blueprint Medicines going out to 2024, and you can see them free on our platform here.Īnother way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies that insiders are buying. Still, the long-term prospects of the business are much more relevant than next year's earnings. So we wouldn't be surprised if the market became a lot more cautious on Blueprint Medicines after today. Often, one downgrade can set off a daisy-chain of cuts, especially if an industry is in decline. Furthermore, there was a cut to the price target, suggesting that the latest news has led to more pessimism about the intrinsic value of the business. Regrettably, they also downgraded their revenue estimates, and the latest forecasts imply the business will grow sales slower than the wider market. The most important thing to take away is that analysts increased their loss per share estimates for next year. It's pretty clear that Blueprint Medicines' revenues are expected to perform substantially worse than the wider industry. Compare this with our data, which suggests that other companies in the same industry are, in aggregate, expected to see their revenue grow 15% per year. This indicates a significant reduction from annual growth of 42% over the last five years. These estimates imply that sales are expected to slow, with a forecast annualised revenue decline of 7.5% by the end of 2023. These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Blueprint Medicines' past performance and to peers in the same industry. As a result it might not be possible to derive much meaning from the consensus price target, which is after all just an average of this wide range of estimates. So we wouldn't be assigning too much credibility to analyst price targets in this case, because there are clearly some widely differing views on what kind of performance this business can generate. The most optimistic Blueprint Medicines analyst has a price target of US$152 per share, while the most pessimistic values it at US$39.00. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. The consensus price target fell 12% to US$79.38, implicitly signalling that lower earnings per share are a leading indicator for Blueprint Medicines' valuation. View our latest analysis for Blueprint Medicines So there's been quite a change-up of views after the recent consensus updates, with the analysts making a serious cut to their revenue forecasts while also expecting losses per share to increase. Yet prior to the latest estimates, the analysts had been forecasting revenues of US$305m and losses of US$8.41 per share in 2023. Losses are predicted to fall substantially, shrinking 23% to US$9.23. This report focused on revenue estimates, and it looks as though the consensus view of the business has become substantially more conservative.įollowing the latest downgrade, the current consensus, from the 17 analysts covering Blueprint Medicines, is for revenues of US$247m in 2023, which would reflect a considerable 9.2% reduction in Blueprint Medicines' sales over the past 12 months. Today is shaping up negative for Blueprint Medicines Corporation ( NASDAQ:BPMC) shareholders, with the analysts delivering a substantial negative revision to next year's forecasts.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |